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Abstract
Background: Lysosomal storage diseases (LSD) are inherited disorders caused by deficiency of lysosomal enzymes
in which early diagnosis is essential to provide timely treatment. This study reports interval values for the activity of
lysosomal enzymes that are deficient in Mucopolysaccharidosis type I, Fabry, Gaucher and Pompe disease, using
dried blood spots on filter paper (DBS) samples in a Brazilian population.
Results: Reference activity values were obtained from healthy volunteers samples for alpha-galactosidase A (4.57 ±
1.37 umol/L/h), beta-glucosidase (3.06 ± 0.99 umol/L/h), alpha-glucosidase (ratio: 13.19 ± 4.26; % inhibition: 70.66 ±
7.60), alpha-iduronidase (3.45 ± 1.21 umol/L/h) and beta-galactosidase (14.09 ± 4.36 umol/L/h).
Conclusion: Reference values of five lysosomal enzymes were determined for a Brazilian population sample.
However, as our results differ from other laboratories, it highlights the importance of establishing specific reference
values for each center.
Introduction
Lysosomal storage diseases (LSD) comprise a group of
more than 40 inherited disorders caused by deficiency
of specific lysosomal hydrolases, which results in the
accumulation of different macromolecules in the lyso-
some, leading to cell dysfunction and progressive clinical
manifestations [1,2].
Most LSD are inherited in an autosomal recessive
manner, with the exception of Hunter, Fabry and Danon
diseases that are X-linked. As a group, LSD have an
incidence of about 1 per 7700 live births [3].
For some LSD as Fabry, Gaucher and Pompe diseases
(FD, GD and PD respectively) and Mucopolysaccharido-
sis type I (MPS I), enzyme replacement therapy has
been widely used as a treatment option, improving the
quality of life and prognosis of these patients. Since
those diseases are all progressive, early diagnosis is an
essential tool for a successful treatment [2].
Biochemical diagnosis of LSD is performed by deter-
mination of enzymatic activities in different biological
fluids (as plasma, leukocytes, fibroblasts and most
recently dried blood spots on filter paper (DBS)), using
fluorimetry, immunocapture and mass spectrometry
assays [4-8]. One of the advantages for the use of DBS
in the diagnosis of LSD is that these samples may be
transported safely through long distances, including
mailing in regular envelopes, because enzyme activities
remain stable for months at room temperature [8]. In
addition, the preparation of a DBS sample requires only
a small amount of blood [9]. These advantages are espe-
cially important in large countries like Brazil, in which
there are few reference laboratories to perform these
assays.
Several studies have demonstrated the feasibility of
using DBS to diagnose LSD [9-11], but it is important to
establish specific reference values to each center, since
enzyme activity may vary due to specific characteristics
of each population and mainly because different assay
conditions. Therefore, the aim of this study was to estab-
lish a reference interval value for the activities of the fol-
lowing lysosomal enzymes in a Brazilian population
sample: alpha-galactosidase A (agal A), beta-glucosidase
(bglu), acid alpha-glucosidase (aglu), alpha-iduronidase
(aidua), which are used for the diagnosis of FD, GD, PD
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and MPS I respectively, and also beta-galactosidase
(bgal), used as a quality control tool.
Methods
This study was performed at Laboratório de Erros Inatos
do Metabolismo (LEIM) from Universidade Federal de
São Paulo (UNIFESP). Research protocols and consent
forms as well as the overall investigation were ethically
and scientifically approved by the Medical Research and
Ethical Committee of UNIFESP (0384/05).
Brazilian healthy volunteers (HV) between the ages of 18
and 80 and without a known genetic or chronic disease
were selected for our study. Samples were collected from
164 individuals (42% male and 58% female). Blood speci-
mens were collected by venipuncture into heparin tubes
and spotted on Whatman® 903 filter paper. Samples
collected at UNIFESP were dried at room temperature for
at least 4 hours and stored at the same day at 4°C in sealed
plastic bags with desiccant (to prevent hydration) until
analysis. Those collected at other locations were prepared
and dried in the same conditions (detailed instructions
were sent to those centers), sealed in plastic bags and sent
to the laboratory in a maximal interval of 5 days, where
they were stored at 4°C. Only high quality DBS, evaluated
by their macroscopic aspect (absence of jagged edges and
clots, and adequate amount of blood on the spot) and bio-
chemically by bgal activity [9,12] were used in this work.
DBS enzyme activity assays were adapted from the
methods described by Chamoles and coworkers [8,13-17].
agal A, aglu, aidua, bgal were assayed on microplates and
bglu was assayed on microtubes. For microplate assays,
1.5 mm diameter (1/16 inch) disks were punched from
each DBS and placed into separate wells in a 96-well blank
plate. For microtube assay, 3.0 mm diameter (1/8 inch)
disks were punched from DBS and placed into separate
2.0 mL microtubes. DBS removal from the wells/tubes
during the analysis was not necessary.
Reaction buffers, fluorogenic substrates, additional
reagents and incubation time used for each DBS assay
are described in Table 1. Assays were performed in
duplicate and with one blank per sample, which was
prepared by adding all reagents except the substrate.
The microplate/microtube reactions and substrate solu-
tion were incubated separately at 37°C in an orbital
shaker. After incubation, substrate solution was added
to blanks and the stop buffer was added to all wells/
tubes. The enzyme product 4-methylumbelliferone was
detected (excitation 365 nm; emission 450 nm) in a
fluorometer SpectraMax M2 (Molecular Devices). Fluor-
escence readings were corrected by blanks, and results
were compared to a 4-methylumbelliferone calibration
curve. Enzymatic activities were expressed as micro-
moles of hydrolyzed substrate per liter of blood per
hour (μmol/L blood/h), with the exception of aglu,
which was expressed as the ratio of neutral and lysoso-
mal isoforms (NaG/AaGIA) and % inhibition of total
acid fraction [9,17].
DBS samples from two healthy individuals have been
used as internal controls in every reaction as well as a
DBS from a confirmed patient. Within-assay coefficients
of variation (CVs) were calculated from an internal con-
trol sample analyzed in all assays.
Data are expressed as mean ± standard deviation (SD).
The parametric Student’s t test was performed to com-
pare mean activity values from both genders in HV
group. The level of significance for statistical analysis
was set at 0.05. All analyses were performed using the
software MINITAB® 15.1.1.0.
Results
bgal activity was analyzed in HV to establish its refer-
ence interval for our population and the range was 7.85
and 22.15 μmol/L blood/h (percentile 5 and 95 respec-
tively). bgal was used as control enzyme, and DBS sam-
ples with bgal activity lower or higher than the normal
range have not been included in this study, as they were
considered inappropriate. The mean, standard deviation
and interval values of the different enzymatic activities
are described in Table 2. A significant difference
between genders was observed for bglu (male: 2.82;
female: 3.23; p = 0.0053) and bgal activities (male: 12.61;
female: 15.17; p = 0.0001 respectively), which could be
due to the higher number of female subjects in the HV
group (69 males versus 95 females).
Our results differ from enzymatic activity values pre-
viously described by Chamoles and coworkers, especially
for aidua activity (our mean activity: 3.45; Chamoles
et al.: 5.50) [8,13-17]. Regarding the study from Cival-
lero and coworkers, in which several lysosomal enzymes
activities were evaluated in another Brazilian sample, a
difference in mean values was also observed, mainly for
bglu activity (our mean value: 3.09; Civallero et al.: 4.92)
[7]. This difference may be explained by sample size
issues, differences in equipment, chemicals or water or
even by ethnic diversity, once the Brazilian population is
known to be composed of a variety of ethnic back-
grounds [18]. However, these differences highlight the
importance of determining specific reference values for
each laboratory or reference center.
Within-assay CVs of internal controls were around
10%, interassay CVs did not exceed 20% and impreci-
sion data are in accordance with other related studies
[8,15,19,20].
Discussion
Different biological materials have been used to diag-
nose LSD patients, but recently several studies have
described the advantages of DBS [9,19,20]. These
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samples can be easily and safely transported by regular
mail, even at room temperature, without altering
enzyme activity [14,15]. In addition, DBS minimizes bio-
logical hazards, since the blood is impregnated in the
filter paper and only a small amount of blood is
required to perform the assay. Moreover, these samples
do not require special storage conditions and the assay
on microplate is easier to perform and less expensive
than other techniques [8,9].
Although we did not evaluate newborns in this study,
it is known that this group has a higher range of enzyme
activity [7,8]. Therefore, it is important to emphasize
that a specific range must be taken into account when
analyzing newborn patients. In addition, it is important
to obtain a reference interval value for this particular
population if these assays would be included in newborn
screening programs.
It is also extremely important to emphasize that in
order to guarantee the quality of diagnosis, blood collec-
tion and DBS samples preparation must be done care-
fully, and the determination of a control enzyme, such
as bgal or hexosaminidase should be performed as a
quality control tool [9,12,14].
Although it has been demonstrated that these enzymes
activities are maintained stable on DBS samples, we sug-
gest that a sample from a healthy volunteer should be
sent to the laboratory for analysis along with the samples
of clinically suspected patients, which could point out
any unexpected decrease of the enzymes activities during
transportation [8,9]. Therefore, the establishment of
reference values from healthy volunteers could be useful
as an additional quality control tool for DBS assays.
We believe that the determination of enzyme activity
using DBS samples is the best option for screening
patients with LSD, especially in high risk groups. This
alternative has several advantages that outweigh an
initial evaluation of suspected subjects using DBS sam-
ples. However, as some of our results differ from other
laboratories, it highlights the importance of establishing
specific reference values for each reference center.
The establishment of reference values for lysosomal
enzyme activities on DBS in a Brazilian population may
Table 1 Assay conditions for each enzyme activity assay
ENZYME Punch
diameter
Reaction buffer Fluorogenic substrate Additional reagents Incubation
time
Stop buffer
alpha-
galactosidase A
1.5 mm 30 μL citrate-phosphate
0.3 M pH 5.0
30 + 30* μL
4 MU-alpha-D-
galactopyranoside 4.2
mM
10 μL
N-acetyl-galactosamine
0.25 M
20 hours 10%
ethylenediamine
1.32 M pH 11.3
alpha-iduronidase 1.5 mm 10 μL
sodium formate 0.2 M pH
2.8
20 + 20* μL
4MU-alpha-L-
idopyranoside
2 mM
10 μL
D-saccharic acid
1,4-lactone monohydrate
3 mM
20 hours 10%
ethylenediamine
1.32 M pH 11.3
beta-glucosidase 3.0 mm 30 μL citrate-phosphate
0.4 M pH 5.2
50 + 50* μL
4MU-beta-D-
glycopyranoside 20 mM
40 μL
sodium taurodeoxicolate
hydrate 0.75%
20 hours 10%
ethylenediamine
1.32 M pH 11.3
alpha-glucosidase 1.5 mm 20 μL
sodium acetate 0.4 M pH
4.0 and 6.5
20 + 20* μL
4MU-alpha-D-
glycopyranoside 2.8 mM
40 μL
acarbose 40 μM
24 hours 10%
ethylenediamine
1.32 M pH 11.3
beta-galactosidase 1.5 mm 20 μL citrate-phosphate
0.1 M pH 4.4
20 + 40* μL
4MU-beta-D-
galactopyranoside 0.8
mM
20 μL sodium chloride
0.9%
3 hours 10%
ethylenediamine
1.32 M pH 11.3
* addition in blank wells after incubation.
MU: methylumbilliferyl.
Table 2 Enzyme activities from HV DBS samples
a-gal A a-idua NaG/AaGIA % inhibition b-glu b-gal
n 164 164 164 164 156 164
mean 4.57 3.45 13.19 70.66 3.06 14.09
SD 1.37 1.21 4.26 7.60 0.99 4.36
interval 1.44 - 10.67 1.40 - 7.78 5.03 - 28.58 36.38 - 87.08 1.51 - 7.23 4.04 - 29.65
Data expressed as μmol/L blood/h.
n = number of samples.
SD = standard deviation.
Interval = established as minimum to maximum.
% inhibition = percent of other alpha-glucosidase isoforms inhibition.
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facilitate the use of this test as a tool for LSD diagnosis
in our country, and even enable the implantation of a
newborn screening program.
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